Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis

SIMPLE SUMMARY: Immunotherapy is an emerging treatment in hepatocellular carcinoma, both alone and in combination. The advent of this new approach raises challenges for the interpretation of response assessment due to the peculiar patterns of mixed responses, pseudoprogression and hyperprogression....

Descripción completa

Detalles Bibliográficos
Autores principales: Rapposelli, Ilario Giovanni, De Matteis, Serena, Lanuti, Paola, Valgiusti, Martina, Bartolini, Giulia, Ulivi, Paola, Marisi, Giorgia, Pedica, Federica, Burgio, Valentina, Frassineti, Giovanni Luca, Cascinu, Stefano, Casadei-Gardini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827490/
https://www.ncbi.nlm.nih.gov/pubmed/33430142
http://dx.doi.org/10.3390/cancers13020213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827490/
https://www.ncbi.nlm.nih.gov/pubmed/33430142
http://dx.doi.org/10.3390/cancers13020213

Ejemplares similares